CGEM Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 19.08%, SMA50 31.65%, SMA200 70.92%). The stock’s 14-day RSI is 73.06 (overbought), while the ATR of 0.92 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 4.46% below its high and over 167.78% above its low. Average 10-day trading volume of 714.72 thousand shares is below the 3-month average of 798.41 thousand, indicating normal recent market interest.

Cullinan Therapeutics, Inc. generated EPS of -$3.68 over the past year. Five-year average earnings growth is -45.66%. Wall Street analysts project EPS growth of -1.6% annually over the next five years. The latest quarter delivered EPS of -$0.77. The next quarter is forecast at -$0.81. Next year's EPS is expected at -$0.61. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $38.00 to $24.00. The high target offers 161.71% upside. The low target suggests 65.29% downside. The mean target is $30.18. This offers 107.85% upside. Cullinan Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -18.95%. The prior quarter beat by 28.92%. Over the last six quarters, Apple has recorded several small beats. These include 2.74% in August 08, 2024.

Cullinan Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.45. This means the shares are trading above this model’s fair value.

Cullinan Therapeutics, Inc. has 59.07 million shares outstanding. The public float is 36.05 million shares, elevated short interest at 12.23% of float. This equals 6.24 million shares. The short ratio is 16.28 days. Institutional investors hold 112.71% of the float. Insiders own 4.54%. Lynx1 Capital Management LP holds 8.96 million shares, UBS Oncology Impact Fund L.P. has 7.65 million shares and LAMPERT MARK N has 4.06 million shares. Over the past six months, insider transactions show net selling. They sold 108.17 thousand shares across 22 transactions.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) closed at $14.52 USD, losing -$0.54 (-3.59%) from the previous close of $15.06. The stock is currently mid-range between its 52-week high and low $5.68 and $16.74. With a market capitalization of about $878.84 million, Cullinan Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.11). Key stats such as the average daily volume over the past year has been around 809.82 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Cullinan Therapeutics, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Nadim Ahmed, the company employs approximately 111 people and listed since January 08, 2021. Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies.

Cullinan Therapeutics, Inc. trades at a P/E ratio of -3.94, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.12 suggesting the stock is closer to book value. The P/FCF stands at -6.37, also above market averages.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) shares are flat 5.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cullinan Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.94. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $35.51, suggesting 144.56% upside. Our AI forecast model points to short-term strength (6.27% over two weeks), a medium-term rise (23.83% over three months), and a longer-term gain (206.34% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cullinan Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.27%, with price expected at $15.43 by May 04, 2026, within a range of $14.66 to $16.27 3-Month Outlook: Projected rise of 23.83%, reaching $17.98 by July 16, 2026, with a range of $17.43 to $18.45. 1-Year Outlook: Projected gain of 206.34%, with price at $44.48 by April 20, 2027, within a range of $42.45 to $56.08.